Goodfellow Pharma

What Goodfellow Pharma does

Goodfellow Pharma Corporation is a privately held pharmaceutical company headquartered in Pasig, Metro Manila, Philippines, with 49 employees and a domestic-only operating footprint. The company markets a portfolio of 17+ branded specialty pharmaceutical products organized across two therapeutic verticals: oncology (chemotherapy agents including pemetrexed, oxaliplatin, gemcitabine, docetaxel, and erlotinib; targeted therapies such as letrozole; and supportive care products including antiemetics, G-CSF, and chemotherapy adjuncts) and nephrology (epoetin alfa for anemia of CKD, enoxaparin, phosphate binders, IV iron sucrose, keto-analogue formulations, and a proprietary gut-flora dietary supplement branded RENADYL). All listed molecules are established off-patent compounds, indicating a branded-generics or biosimilars distribution and marketing model rather than novel drug development.

The business operates on a sales-led, direct-to-provider go-to-market, selling to Philippine hospitals, clinics, and healthcare professionals through phone, email, and a website-based inquiry channel. Pricing is not publicly disclosed and is presumed to be quote-based and negotiated per institution or per product. Revenue is generated through one-time product sales of branded specialty medications, with no disclosed subscription, licensing, or recurring revenue model. The company emphasizes affordability and accessibility for Filipino patients as its core value proposition, positioning itself as a domestic alternative to multinational pharmaceutical brands in two high-burden therapeutic areas (cancer and chronic kidney disease).

Goodfellow has no disclosed parent company, no external funding rounds, no patents or trademarks on file, no certifications, no partnerships, and no management team information publicly available. The technology stack is conventional — a template-based marketing website with no APIs, apps, AI capabilities, or proprietary platform infrastructure. The company is actively operating as of 2024 but presents limited transparency on ownership, financials, manufacturing versus distribution structure, and regulatory standing.

Name

Goodfellow Pharma

Legal name

Goodfellow Pharma Corporation

Website

https://goodfellowpharma.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Goodfellow Pharma Corporation is a privately held Philippine pharmaceutical company that markets a portfolio of branded oncology and nephrology medications (chemotherapy, targeted therapies, anemia and CKD treatments) directly to Philippine hospitals, clinics, and healthcare providers.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Nephrology & Urology Pharmaceuticals (HLAIAAAM), Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)

Keywords

• Nephrology medications
• Oncology pharmaceuticals
• Chemotherapy drugs
• Kidney disease treatments
• Cancer care medicines

Headquarters

HQ city

Pasig

HQ country

Philippines

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: Goodfellow Pharma generates revenue through the sale of specialized pharmaceutical medications in the oncology and nephrology therapeutic categories. The company manufactures and distributes branded medications targeting cancer treatments and kidney-related conditions, selling directly to healthcare providers and institutions in the Philippine market.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Goodfellow Pharma Corporation manufactures and distributes a specialized portfolio of branded pharmaceutical medications focused on nephrology and oncology therapeutic areas. The company sells these medications directly to healthcare providers, hospitals, and clinics in the Philippines, covering treatments for chronic kidney disease, anemia, dialysis support, chemotherapy, targeted cancer therapies, and supportive care for cancer patients.

Product overview

Goodfellow Pharma is a Philippine pharmaceutical company offering a portfolio of specialized medicines across two therapeutic areas. Their product portfolio comprises oncology treatments including chemotherapy agents (PEMEX, ZEFEI, HENTAXEL, HENPLATIN), targeted therapies (ERLOX, HENTROZOLE), supportive care products for cancer treatment side effects (HENSETRON, WHITE-C, ONCOBLOC, ZILONGJIN-8), and anemia management (EPOSINO 10000UI, TPIAO). Their nephrology range includes treatments for anemia (EPOSINO), anticoagulation (ENOMAX), phosphate management (FOSBIND), iron deficiency (FERROFER), nutritional support (KETOBEST), and a gut-based dietary supplement (RENADYL). All products are designed to be high-quality and affordable for Filipino patients.

Differentiator

Problem solved

Functional benefit

Products and services

• EPOSINO Epoetin alfa treats anemia in chronic kidney disease by boosting red blood cell production, improving quality of life, especially in dialysis patients. Available in 2000UI, 6000UI, and 4000UI.
• ENOMAX Enoxaparin sodium is an anticoagulant used to prevent and treat blood clots in conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and post-surgical complications. Available in 40mg and 60mg.
• FOSBIND Fosbind is a medication used to manage elevated phosphate levels in patients with chronic kidney disease (CKD) who are undergoing dialysis, helping to prevent complications associated with high phosphate levels.
• FERROFER Iron sucrose is an intravenous supplement used to treat iron deficiency anemia in patients with chronic kidney disease, especially those on dialysis. It helps restore iron levels essential for producing healthy red blood cells.
• KETOBEST Formulated for chronic kidney disease, Ketobest combines ketoanalogues and essential amino acids to support kidney health, maintain muscle mass, and reduce urea production.
• RENADYL Renadyl is a proprietary oral dietary supplement, scientifically formulated and clinically tested to help reduce waste metabolites in the bowel and stabilize healthy gut flora for nephrology patients.
• PEMEX Pemetrexed is a chemotherapy drug used to treat non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma by inhibiting cancer cell growth. Available in 500mg and 100mg.
• HENSETRON Tropisetron HCl prevents and manages nausea and vomiting from chemotherapy or surgery by blocking serotonin receptors.
• HENPLATIN Oxaliplatin treats colorectal cancer by disrupting DNA replication in cancer cells. It inhibits cell growth and is often used with other drugs to boost treatment effectiveness.
• TPIAO Recombinant Human Thrombopoietin (rhTPO) is used to stimulate the production of platelets in the blood. It helps treat conditions like chronic immune thrombocytopenia (ITP) and other disorders where platelet production is impaired.
• ZEFEI Gemcitabine HCl is used to treat various types of cancer, including pancreatic, non-small cell lung, and bladder cancers. It works by interfering with DNA replication in cancer cells. Available in 1g and 200mg.
• EPOSINO 10000UI Eposino 10000UI is used to treat anemia associated with cancer and chemotherapy. It stimulates the production of red blood cells, helping to improve oxygen delivery and reduce fatigue in cancer patients undergoing treatment.
• HENTAXEL Docetaxel is used to treat cancers such as breast, prostate, lung, and stomach. It inhibits cell division, slowing cancer growth and spread. Available in 20mg and 80mg.
• WHITE-C Filgrastim is used to stimulate the production of white blood cells, specifically neutrophils. It helps prevent infections in patients undergoing chemotherapy, bone marrow disorders, or certain types of cancer.
• HENTROZOLE Letrozole is used primarily to treat hormone receptor-positive breast cancer in postmenopausal women. It works by lowering estrogen levels, which helps slow or stop the growth of estrogen-dependent cancer cells.
• ZILONGJIN-8 Zilongjin-8 is used with chemotherapy drugs to enhance their effectiveness and reduce side effects. It helps maintain blood levels, safeguards the liver and kidneys, and mitigates the drop in white blood cells caused by DDP and Cytoxan.
• ERLOX Erlotinib is used to treat non-small cell lung cancer (NSCLC) and pancreatic cancer. It works by inhibiting the epidermal growth factor receptor (EGFR), which helps slow the growth of cancer cells.
• ONCOBLOC Oncobloc alleviates gastrointestinal issues, such as diarrhea, caused by chemotherapy or radiation treatments, improving patient comfort and quality of life during cancer therapy.

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators2 records

Recent moves4 records

Expansion highlights3 records

Regional players

• Mega Lifesciences: Thailand-based pharmaceutical company distributing branded generics and specialty medications across Southeast Asia including the Philippines. Comparable as a regional specialty-pharma distributor expanding into the Philippine hospital channel.
• Kalbe Farma: Indonesia's largest pharmaceutical company with branded generics and specialty pharma operations across Southeast Asia. Comparable regional specialty-pharma playbook, though primarily Indonesia-focused and not directly competing in the Philippines today.

Broad incumbents

• Unilab (United Laboratories): Philippines' largest domestic pharmaceutical manufacturer and distributor with a broad branded-generic portfolio across therapeutic areas including oncology and nephrology. Directly comparable as a Philippine-headquartered pharma company selling affordable branded medications through hospital and retail channels, but at much larger scale and broader scope.
• Roche Philippines: Philippine arm of Roche, a global oncology leader. Competes directly in oncology chemotherapy and supportive care where Goodfellow sells PEMEX, ZEFEI, and HENTAXEL, but with innovator franchises and clinical data advantages.
• Astellas Pharma Philippines: Philippine subsidiary of Astellas, with a strong nephrology franchise (including treatments relevant to Goodfellow's nephrology portfolio). Comparable in the nephrology therapeutic overlap but with patented products and global scale.
• Pfizer Philippines: Philippine affiliate of Pfizer, distributing innovative oncology and supportive-care products. Competes in the same oncology therapeutic space as Goodfellow but at much larger scale with patented innovator therapies.

Direct peers

• Hizon Laboratories: Philippine pharmaceutical company producing branded generic and specialty medications sold to hospitals and clinics. Directly comparable as a domestic specialty pharma of similar size targeting hospital and prescriber channels.
• Lloyd Laboratories: Philippine-based pharmaceutical manufacturer specializing in branded generics across multiple therapeutic categories including oncology and supportive care. Closely comparable as a domestic Philippine specialty pharma with hospital-channel distribution and similar affordability positioning.
• Westmont Pharmaceuticals: Philippine-based pharmaceutical company marketing specialty and branded-generic products to healthcare providers. Comparable in focus on specialty therapeutic categories and direct-to-institution sales motion.

Emerging players

• Sandoz (Philippines / Novartis): Global leader in biosimilars and generic oncology supportive-care drugs with Philippines operations. Comparable as a generic/biosimilar supplier in the same oncology and nephrology INN spaces Goodfellow competes in, but with global biosimilar scale.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/goodfellow-pharma

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Goodfellow Pharma